In addition, Li and co-workers (33) demonstrated that the combination of fruquintinib with the anti-PD-1 antibody sintilimab synergistically inhibited colorectal cancer growth by remodeling the immune landscape within tumors, including increased infiltration and activation of cytotoxic T cells, and a reduction in immunosuppressive (CD11b+ Gr1+) cell populations. This evidence concerns the gene ITGAM and colorectal cancer.